A Phase 2 proof of concept study of ACP-196 alone in combination with Pembrolizumab in subjects with advanced or metastatic pancreatic cancer.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Acerta Pharma
Start Date
May 1, 2015
End Date
May 24, 2018
Administered By
Duke Cancer Institute
Awarded By
Acerta Pharma
Start Date
May 1, 2015
End Date
May 24, 2018